Neuromuscular Disease in the ICU

  • Christopher L. Kramer
  • Alejandro A. RabinsteinEmail author


Assessing where a patient is along the spectrum of neuromuscular respiratory failure requires knowledge of respiratory physiology and pathophysiology, the evolution of clinical features, and knowledge of how to interpret diagnostic studies in the context of their limitations. Ultimately, this information can be employed to discern or predict the need for ICU admission and ventilatory support. Of equal importance is a thorough understanding of the most common causes of neuromuscular respiratory failure, how to diagnose them, and their associated complications and treatments. This chapter informs the reader how to approach and manage the patient with limb, bulbar, and respiratory weakness and equips them with the tools to diagnose and treat the most common causes of primary and secondary neuromuscular weakness.


Neuromuscular respiratory failure Guillain-Barre syndrome Myasthenia gravis Myasthenic crisis Intensive care unit acquired weakness Critical illness neuromyopathy Critical illness myopathy Critical illness polyneuropathy 


  1. 1.
    Wijdicks EFM. The neurology of acutely failing respiratory mechanics. Ann Neurol. 2017;81:485–94.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Wijdicks EFM. Management of acute neuromuscular disorders. Handb Clin Neurol. 2017;140(3):229–37.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Greene-Chandos D, Torbey M. Critical care of neuromuscular disorders. Continuum. 2018;24(6):1753–75.PubMedPubMedCentralGoogle Scholar
  4. 4.
    Howard RS. Respiratory failure because of neuromuscular disease. Curr Opin Neurol. 2016;29(5):592–601.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Irfan M, Selim B, Rabinstein AA, St. Louis EK. Neuromuscular disorders and sleep in critically ill patients. Crit Care Clin. 2015;31(3):533–50.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Cabrera Serrano M, Rabinstein AA. Usefulness of pulmonary function tests and blood gases in acute neuromuscular respiratory failure. Eur J Neurol. 2012;19(3):452–6.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Lawn ND, Fletcher DD, Henderson RD, Wolter TD, Wijdicks EF. Anticipating mechanical ventilation in Guillain-Barre syndrome. Arch Neurol. 2001;58(6):893–8.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Walterspacher S, Kirchberger A, Lambeck J, et al. Respiratory muscle assessment in acute Guillain-Barre syndrome. Lung. 2016;194:821–8.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Kramer CL, McCullough M, Wijdicks EF. Teaching video neuroimages: how to unmask respiratory strength confounded by facial diplegia. Neurology. 2015;84:e57–8.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Boon AJ, O’Gorman C. Ultrasound in the assessment of respiration. J Clin Neurophysiol. 2016;33:112–9.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Caulfield AF, Flower O, Pineda JA, Uddin S. Emergency neurological life support: acute non-traumatic weakness. Neurocrit Care. 2017;27(Suppl 1):29–50. Scholar
  12. 12.
    Walgaard C, Lingsma HF, van Doorn PA, et al. Tracheostomy or not: prediction of prolonged mechanical ventilation in Guillain-Barre syndrome. Neurocrit Care. 2017;26:6–13.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Lawn ND, Wijdicks EF. Post-intubation pulmonary function test in Guillain-Barre syndrome. Muscle Nerve. 2000;23:613–6.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Cabrera Serrano M, Rabinstein AA. Causes and outcomes of acute neuromuscular respiratory failure. Arch Neurol. 2010;67(9):1089–94.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Yuki N, Hartung HP. Guillain-Barre syndrome. N Engl J Med. 2012;366:2294–304.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Dos Santos T, Rodriguez A, Almiron M, et al. Zika virus and the Guillain-Barre syndrome - case series from seven countries. N Engl J Med. 2016;375:1598–601.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Gold CA, Josephson SA. Anticipating the challenges of Zika virus and the incidence of Guillain-Barre syndrome. JAMA Neurol. 2016;73:905–6.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    van den Berg B, Walgaard C, Drenthen J, Fokke C, Jacobs BC, van Doorn PA. Guillain-Barre syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol. 2014;10:469–82.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Walgaard C, Lingsma HF, Ruts L, et al. Prediction of respiratory insufficiency in Guillain-Barre syndrome. Ann Neurol. 2010;67:781–7.PubMedPubMedCentralGoogle Scholar
  20. 20.
    Zaeem Z, Siddiqi ZA, Zochodne DW. Autonomic involvement in Guillain-Barre syndrome: an update. Clin Auton Res. 2018;29(3):289–99.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Vucic S, Cairns KD, Black KR, Chong PS, Cros D. Neurophysiologic findings in early acute inflammatory demyelinating polyradiculoneuropathy. Clin Neurophysiol. 2004;115:2329–35.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Kokubun N, Nishibayashi M, Uncini A, Odaka M, Hirata K, Yuki N. Conduction block in acute motor axonal neuropathy. Brain. 2010;133:2897–908.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barre syndrome. Cochrane Database Syst Rev. 2014;(7):CD002063.Google Scholar
  24. 24.
    Raphael JC, Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain-Barre syndrome. Cochrane Database Syst Rev. 2012;(2):CD001798.Google Scholar
  25. 25.
    Fokke C, van den Berg B, Drenthen J, Walgaard C, van Doorn PA, Jacobs BC. Diagnosis of Guillain-Barre syndrome and validation of Brighton criteria. Brain. 2014;137:33–43.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    van den Berg B, Bunschoten C, van Doorn PA, Jacobs BC. Mortality in Guillain-Barre syndrome. Neurology. 2013;80:1650–4.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Walgaard C, Lingsma HF, Ruts L, van Doorn PA, Steyerberg EW, Jacobs BC. Early recognition of poor prognosis in Guillain-Barre syndrome. Neurology. 2011;76:968–75.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Drachman DB. Myasthenia Gravis. Semin Neurol. 2016;36:419–24.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Nicolle MW. Myasthenia Gravis and Lambert-Eaton Myasthenic syndrome. Continuum (Minneap Minn). 2016;22:1978–2005.Google Scholar
  30. 30.
    Skeie GO, Apostolski S, Evoli A, et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol. 2010;17:893–902.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Gilchrist JM, Massey JM, Sanders DB. Single fiber EMG and repetitive stimulation of the same muscle in myasthenia gravis. Muscle Nerve. 1994;17:171–5.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Gajdos P, Chevret S, Toyka KV. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev. 2012;12:CD002277.PubMedPubMedCentralGoogle Scholar
  33. 33.
    Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann Neurol. 1997;41:789–96.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Mandawat A, Kaminski HJ, Cutter G, Katirji B, Alshekhlee A. Comparative analysis of therapeutic options used for myasthenia gravis. Ann Neurol. 2010;68:797–805.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Iorio R, Damato V, Alboini PE, Evoli A. Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis. J Neurol. 2015;262:1115–9.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Seneviratne J, Mandrekar J, Wijdicks EF, Rabinstein AA. Noninvasive ventilation in myasthenic crisis. Arch Neurol. 2008;65:54–8.PubMedPubMedCentralGoogle Scholar
  37. 37.
    Seneviratne J, Mandrekar J, Wijdicks EF, Rabinstein AA. Predictors of extubation failure in myasthenic crisis. Arch Neurol. 2008;65:929–33.PubMedPubMedCentralGoogle Scholar
  38. 38.
    Rabinstein AA, Mueller-Kronast N. Risk of extubation failure in patients with myasthenic crisis. Neurocrit Care. 2005;3:213–5.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Kalita J, Kohat AK, Misra UK. Predictors of outcome of myasthenic crisis. Neurol Sci. 2014;35:1109–14.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Hermans G, Van den Berghe G. Clinical review: intensive care unit acquired weakness. Crit Care. 2015;19:274.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Jolley SE, Bunnell AE, Hough CL. ICU-acquired weakness. Chest. 2016;150:1129–40.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Kress JP, Hall JB. ICU-acquired weakness and recovery from critical illness. N Engl J Med. 2014;370:1626–35.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Kramer CL. ICU-acquired weakness. Neurol Clin. 2017;35(4):723–36. Scholar
  44. 44.
    Batt J, dos Santos CC, Cameron JI, Herridge MS. Intensive care unit-acquired weakness: clinical phenotypes and molecular mechanisms. Am J Respir Crit Care Med. 2013;187:238–46.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Jung B, Moury PH, Mahul M, et al. Diaphragmatic dysfunction in patients with ICU-acquired weakness and its impact on extubation failure. Intensive Care Med. 2016;42:853–61.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Kramer CL, Boon AJ, Harper CM, Goodman BP. Compound muscle action potential duration in critical illness neuromyopathy. Muscle Nerve. 2018;57(3):395–400. Scholar
  47. 47.
    Hermans G, De Jonghe B, Bruyninckx F, Van den Berghe G. Interventions for preventing critical illness polyneuropathy and critical illness myopathy. Cochrane Database Syst Rev. 2014:CD006832.Google Scholar
  48. 48.
    Kayambu G, Boots R, Paratz J. Physical therapy for the critically ill in the ICU: a systematic review and meta-analysis. Crit Care Med. 2013;41:1543–54.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Burtin C, Clerckx B, Robbeets C, et al. Early exercise in critically ill patients enhances short-term functional recovery. Crit Care Med. 2009;37:2499–505.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Kho ME, Truong AD, Zanni JM, et al. Neuromuscular electrical stimulation in mechanically ventilated patients: a randomized, sham-controlled pilot trial with blinded outcome assessment. J Crit Care. 2015;30:32–9.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Jones S, Man WD, Gao W, Higginson IJ, Wilcock A, Maddocks M. Neuromuscular electrical stimulation for muscle weakness in adults with advanced disease. Cochrane Database Syst Rev. 2016;10:CD009419.PubMedPubMedCentralGoogle Scholar
  52. 52.
    Hermans G, Van Mechelen H, Clerckx B, et al. Acute outcomes and 1-year mortality of intensive care unit-acquired weakness. A cohort study and propensity-matched analysis. Am J Respir Crit Care Med. 2014;190:410–20.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Sharshar T, Bastuji-Garin S, Stevens RD, et al. Presence and severity of intensive care unit-acquired paresis at time of awakening are associated with increased intensive care unit and hospital mortality. Crit Care Med. 2009;37:3047–53.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Wieske L, Dettling-Ihnenfeldt DS, Verhamme C, et al. Impact of ICU-acquired weakness on post-ICU physical functioning: a follow-up study. Crit Care. 2015;19:196.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Harvey MA, Davidson JE. Postintensive care syndrome: right care, right now…and later. Crit Care Med. 2016;44:381–5.CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Sacanella E, Perez-Castejon JM, Nicolas JM, et al. Functional status and quality of life 12 months after discharge from a medical ICU in healthy elderly patients: a prospective observational study. Crit Care. 2011;15:R105.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Guarneri B, Bertolini G, Latronico N. Long-term outcome in patients with critical illness myopathy or neuropathy: the Italian multicentre CRIMYNE study. J Neurol Neurosurg Psychiatry. 2008;79:838–41.CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Rabinstein AA. Noninvasive ventilation for neuromuscular respiratory failure: when to use and when to avoid. Curr Opin Crit Care. 2016;22(2):94–9.PubMedPubMedCentralGoogle Scholar
  59. 59.
    Wijdicks EF, Henderson RD, McClelland RL. Emergency intubation for respiratory failure in Guillain-Barre syndrome. Arch Neurol. 2003;60:947–8.CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Wijdicks EF, Roy TK. BiPAP in early Guillain-Barre syndrome may fail. Can J Neurol Sci. 2006;33:105–6.CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome. Plasma exchange/Sandoglobulin Guillain-Barre Syndrome Trial Group. Lancet. 1997;349:225–30.Google Scholar
  62. 62.
    van Koningsveld R, Schmitz PI, Meche FG, et al. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barre syndrome: randomised trial. Lancet. 2004;363:192–6.CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Barth D, Nabavi Nouri M, Ng E, Nwe P, Bril V. Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology. 2011;76:2017–23.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Christopher L. Kramer
    • 1
  • Alejandro A. Rabinstein
    • 2
    Email author
  1. 1.University of ChicagoChicagoUSA
  2. 2.Mayo ClinicRochesterUSA

Personalised recommendations